Panthera Biopartners appoints Martyn Jellett as Associate Director Business Development to support growing commercial team

Independent clinical trial SMO (Site Management Organisation) Panthera Biopartners has appointed Martyn Jellet as Associate Director Business Development to support its expanding commercial team as the company continues to prosper and expand. Martyn has over 25 years experience in professional sales and business development and has extensive knowledge of the pharmaceutical and medical industry.

Panthera, which launched in 2019, has become the leading UK SMO and has the most experienced management team in the industry. Its new refined SMO model, and reputation for providing rapid speed of start up and first patient in, has attracted significant interest from pharma and CROs across the world resulting in an increasingly strong pipeline. Panthera is working closely with 10 out of the top 12 pharma companies and seven of the top CROs. To meet this growing demand Panthera’s commercial team has continued to grow and there are now eight members of the team who are dedicated to liaison with the company’s clients.

In his role as Associate Director Business Development, Martyn will be working with Panthera’s commercial team to identify, negotiate and secure further strategic partnerships and contracts with biotech and pharma companies, as well as academic and research institutions.

Chris Dodd, Panthera’s Chief Commercial Officer commented “We are continuing to build a world class team and are really delighted that Martyn has chosen to join us. Martyn has a proven track record of  exceeding sales targets and winning multi-million pound contracts. His experience will be invaluable to us as we continue to grow and build on the expansion of the company”.